EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Fc Effector Function of Immune Checkpoint Blocking Antibodies in Oncology

Romane Martineau iD, Sandrine Susini iD, Aurelien Marabelle iD

Immunological Reviews · 2024-11 · 328 (1) · 334-349

DOI: 10.1111/imr.13427 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Immunological Reviews, online erschienen am 11.12.2024. Verfasst von Romane Martineau und 2 weiteren Autor:innen. Beteiligte Einrichtung: Université Paris Saclay, Le Kremlin-Bicetre, France. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Neoplasms. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 133 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Antagonistic monoclonal antibodies (mAbs) targeting inhibitory immune checkpoints have revolutionized the field of oncology. CTLA‐4, PD‐1, and LAG3 are three co‐inhibitory receptors, which can be expressed by subsets of T cells and which play a role in the regulation of adaptive immune responses. Blocking these immune checkpoints receptors (or their ligands) with antagonistic antibodies can lead to tumor regressions and lasting remissions in some patients with cancer. Two anti‐CTLA4, six anti‐PD1, three anti‐PD‐L1, and one anti‐LAG3 antibodies are currently approved by the FDA and EMA. Their mechanism of action, safety, and efficacy are linked to their affinity with Fc gamma receptors (FcγR) (so called “effector functions”). The anti‐CTLA‐4 antibodies ipilimumab (IgG1) and tremilimumab (IgG2a), and the anti‐PD‐L1 avelumab (IgG1) have isotypes with high affinity for activating FcγR and thereby can induce ADCC/ADCP. The effector function is required for the in vivo efficacy of anti‐CTLA4 antibodies. For anti‐PD(L)1 antibodies, where a pure antagonistic function (“checkpoint blockade”) is sufficient, some mAbs are IgG1 but have been mutated in their Fc sequence (e.g., durvalumab and atezolizumab) or are IgG4 (e.g., nivolumab and pembrolizumab) to have low affinity for FcγR. Here, we review the impact of FcγR effector function on immune checkpoint blockers safety and efficacy in oncology.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immune Checkpoint InhibitorsNeoplasmsAnimalsHumansAntibodies, MonoclonalAntibody-Dependent Cell CytotoxicityAntineoplastic Agents, ImmunologicalCTLA-4 AntigenImmune Checkpoint ProteinsImmunoglobulin Fc FragmentsImmunotherapyReceptors, IgG

Stichwörter der Autor:innen

FcγRimmune checkpointmonoclonal antibody

Substanzen

Antibodies, MonoclonalAntineoplastic Agents, ImmunologicalCTLA-4 AntigenImmune Checkpoint InhibitorsImmune Checkpoint ProteinsImmunoglobulin Fc FragmentsReceptors, IgG

Autor:innen und Institutionen

  • Université Paris Saclay, Le Kremlin-Bicetre, France.
  • Centre d'Investigation Clinique BIOTHERIS, CIC 1428, Institut National de la Santé et de la Recherche Médicale (INSERM), Villejuif, France.
  • Translational Immunotherapy Research Laboratory, Gustave Roussy, Villejuif, France.

ORCID-Profile: Romane Martineau, Sandrine Susini, Aurelien Marabelle

Zitieren

APA

Martineau, R., Susini, S., & Marabelle, A. (2024). Fc Effector Function of Immune Checkpoint Blocking Antibodies in Oncology. Immunological Reviews, 328(1), 334-349. https://doi.org/10.1111/imr.13427

Vancouver

Martineau R, Susini S, Marabelle A. Fc Effector Function of Immune Checkpoint Blocking Antibodies in Oncology. Immunological Reviews. 2024;328(1):334-349. doi:10.1111/imr.13427

BibTeX
@article{Martineau2024,
  author = {Martineau, Romane and Susini, Sandrine and Marabelle, Aurelien},
  title = {Fc Effector Function of Immune Checkpoint Blocking Antibodies in Oncology},
  journal = {Immunological Reviews},
  year = {2024},
  volume = {328},
  number = {1},
  pages = {334--349},
  doi = {10.1111/imr.13427}
}
Kostenlos starten →